secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096796
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial stockholders approve 4x increase in equity plan shares to 2M; directors re-elected
--------------------------------------------------------------------------------

- Amendment No. 6 to 2017 Equity Incentive Plan approved, raising authorized shares from 500,000 to 2,000,000.
- J. Kermit Anderson and James W. Newman Jr. re-elected as Class III directors through 2027.
- Marcum LLP ratified as independent auditor for fiscal year ending December 31, 2024.
- Advisory vote on executive compensation approved; board sets future advisory vote every three years.
- Broker non-votes of ~2.3M shares on director election and plan amendment, reflecting significant institutional abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024096796/0001213900-24-096796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024096796/ea0220869-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer